(S)-(+)-2-氨基-2-苯基丁酸 | 52247-77-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-(+)-2-氨基-2-苯基丁酸
• 英文名称: (S)-(-)-α-ethyl-phenylglycine
• 英文别名: (S)-2-amino-2-phenylbutyric acid；(S)-2-Amino-2-phenyl-buttersaeure；(2S)-2-azaniumyl-2-phenylbutanoate
• CAS: 52247-77-5
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.219
• InChiKey: UBXUDSPYIGPGGP-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  (S)-(+)-2-氨基-2-苯基丁酸 在 盐酸 、 乙醇 作用下， 生成 ethyl (S)-2-amino-2-phenylbutanoate
  参考文献：
  名称：

  OPTICALLY ACTIVE 5,5'-DISUBSTITUTED HYDANTOINS¹

  摘要：

  DOI：

  10.1021/ja01351a028
• 作为产物：
  描述：

  (+/-)-2-formylamino-2-phenyl-butyric acid 在 硫酸 作用下， 生成 (S)-(+)-2-氨基-2-苯基丁酸
  参考文献：
  名称：

  OPTICALLY ACTIVE 5,5'-DISUBSTITUTED HYDANTOINS¹

  摘要：

  DOI：

  10.1021/ja01351a028

文献信息

• Efficient Biocatalytic Synthesis of Highly Enantiopureα-Alkylated Arylglycines and Amides
  作者：Mei-Xiang Wang、Shuan-Jun Lin、Jun Liu、Qi-Yu Zheng

  DOI：10.1002/adsc.200303219

  日期：2004.3

  racemic α-alkylarylglycine amides including 1-amino-1-carbamoyl-1,2,3,4-tetrahydronaphthalene underwent efficient biocatalytic hydrolysis under very mild conditions to afford the corresponding (S)-α-alkylarylglycines and (R)-α-alkylarylglycine amides in excellent yields with enantiomeric excesses higher than 99.5%. Both the reaction rate and enantioselectivity of biocatalytic kinetic resolution were strongly

  包括1-氨基-1-氨基甲酰基-1,2,3,4-四氢萘在内的许多外消旋α-烷基芳基甘氨酸酰胺在非常温和的条件下进行了有效的生物催化水解，得到相应的（S）-α-烷基芳基甘氨酸和（R）- α-烷基芳基甘氨酸酰胺具有优异的收率，对映体过量高于99.5％。生物催化动力学拆分的反应速率和对映选择性都强烈取决于取代基的性质和底物苯环上的取代方式。相反，在含腈水化酶/酰胺酶的微生物红球菌的催化下，未观察到源自苯乙酮的Strecker腈的有效生物转化。sp。AJ270全细胞催化剂。结合酰胺的化学水解，该生物转化过程从容易获得的外消旋酰胺提供了两种对映体形式的α-取代的芳基甘氨酸的有效合成。
• Evaluation of the Edman degradation product of vancomycin bonded to core-shell particles as a new HPLC chiral stationary phase
  作者：Garrett Hellinghausen、Diego A. Lopez、Jauh T. Lee、Yadi Wang、Choyce A. Weatherly、Abiud E. Portillo、Alain Berthod、Daniel W. Armstrong

  DOI：10.1002/chir.22985

  日期：2018.9

  macrocyclic glycopeptide‐based chiral stationary phase (CSP), prepared via Edman degradation of vancomycin, was evaluated as a chiral selector for the first time. Its applicability was compared with other macrocyclic glycopeptide‐based CSPs: TeicoShell and VancoShell. In addition, another modified macrocyclic glycopeptide‐based CSP, NicoShell, was further examined. Initial evaluation was focused on the complementary

  通过对万古霉素的Edman降解制备的修饰的基于大环糖肽的手性固定相（CSP）被首次评估为手性选择剂。将其适用性与其他基于大环糖肽的CSP（TeicoShell和VancoShell）进行了比较。此外，还进一步检查了另一种基于大环糖肽的修饰CSP NicoShell。最初的评估集中在与这些糖肽的互补行为上。根据以前的工作，使用了一种筛选方法，用于对50种手性化合物的对映体分离，其中包括氨基酸，农药，兴奋剂和多种药物。使用表面多孔（核-壳）颗粒载体可实现快速有效的手性分离。总体，万古霉素埃德曼降解产物（EDP）与TeicoShell类似，在极性离子模式下对酸性化合物具有高对映选择性。使用液相色谱-质谱联用EDP同时分离5种外消旋脯氨酸的对映异构体，时间约为3分钟。其他亮点包括同时用VancoShell液相色谱分离rac-amphetamine和rac-methamphetamine，用Nico
• [EN] FAR SUPERIOR OXIDATION CATALYSTS BASED ON MACROCYCLIC COMPOUNDS<br/>[FR] CATALYSEURS D'OXYDATION NETTEMENT SUPÉRIEURS À BASE DE COMPOSÉS MACROCYCLIQUES
  申请人：UNIV CARNEGIE MELLON

  公开号：WO2017053564A1

  公开（公告）日：2017-03-30

  An especially robust compound and its derivative metal complexes that are approximately one hundred-fold superior in catalytic performance to the previously invented TAML analogs is provided having the formula (I) wherein Y1, Y2, Y3 and Y4 are oxidation resistant groups which are the same or different and which form 5- or 6-membered rings with a metal, M, when bound to D; at least one Y incorporates a group that is significantly more stable towards nucleophilic attack than the organic amides of TAML activators; D is a metal complexing donor atom, preferably N; each X is a position for addition of a labile Lewis acidic substituent such as (i) H, deuterium, (ii) Li, Na, K, alkali metals, (iii) alkaline earth metals, transition metals, rare earth metals, which may be bound to one or more than one D, (iv) or is unoccupied with the resulting negative charge being balanced by a nonbonded counteraction; at least one Y may contain a site that is labile to acid dissociation, providing a mechanism for shortening complex lifetime. The new complexes deliver catalytic performances that promise to revolutionize multiple oxidation technology spaces including water purification.

  提供了一种特别强大的化合物及其衍生金属配合物，其催化性能大约比先前发明的TAML类似物优越一百倍，其化学式为（I），其中Y1、Y2、Y3和Y4是抗氧化的基团，可以相同也可以不同，并且与金属M结合时形成5-或6-成员环；至少一个Y包含一个对亲核攻击更稳定的基团，比TAML活化剂的有机酰胺更稳定；D是金属络合给体原子，优选为N；每个X是用于添加易失去的Lewis酸性取代基的位置，例如（i）H、氘，（ii）Li、Na、K、碱金属，（iii）碱土金属、过渡金属、稀土金属，可以与一个或多个D结合，（iv）或者未被占据，由非键合的对应作用平衡产生的负电荷；至少一个Y可能包含一个易于酸解离的位点，提供缩短配合物寿命的机制。这些新配合物提供了催化性能，有望彻底改变多种氧化技术领域，包括水净化。
• Dolastatin 15 derivatives
  申请人：Janssen Bernd

  公开号：US20060270606A1

  公开（公告）日：2006-11-30

  Compounds of the present invention include cell growth inhibitors which are peptides of Formula I, A-B-D-E-F-(G) r -(K) s -L   (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a β-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group. The present invention also includes a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.

  本发明的化合物包括细胞生长抑制剂，其为式I中的肽，A-B-D-E-F-(G)r-(K)s-L，以及其酸盐，其中A、B、D、E、F、G和K是α-氨基酸残基，s和r各自独立地为0或1。L是单价基团，例如氨基、N-取代氨基、β-羟胺基、肼基、烷氧基、硫烷氧基、氨氧基或氧化肟基。本发明还包括一种用于治疗哺乳动物（例如人类）癌症的方法，包括向哺乳动物中给予式I化合物的有效量，以一种药学上可接受的组合物形式。
• 2-Aminooxazolines as TAAR1 ligands
  申请人：Galley Guido

  公开号：US20080261920A1

  公开（公告）日：2008-10-23

  The invention relates to compounds of formula I wherein X, Y, R 1 , R 2 , and n are as defined herein or to a pharmaceutically suitable acid addition salt thereof. The invention also relates to pharmaceutical compositions containing such compounds and methods for the treatment of diseases related to the biological function of the trace amine associated receptors, which diseases include depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.

  本发明涉及化合物I的公式，其中X，Y，R1，R2和n如本文所定义，或其药学上适宜的酸加盐。本发明还涉及含有这种化合物的制药组合物和治疗与微量胺相关受体的生物学功能相关的疾病的方法，这些疾病包括抑郁症、焦虑症、双相情感障碍、注意力缺陷多动障碍、压力相关障碍、精神障碍、精神分裂症、神经系统疾病、帕金森病、神经退行性疾病、阿尔茨海默病、癫痫、偏头痛、物质滥用和代谢性疾病、进食障碍、糖尿病、糖尿病并发症、肥胖症、血脂异常、能量消耗和吸收障碍、体温稳态障碍和功能障碍、睡眠和昼夜节律障碍以及心血管疾病。